Thus, high-profile studies investigating feasibility of the modality in terms of adverse effects seem premature.doi:10.1038/nrurol.2012.133GuillonneauBertrandNature Reviews UrologyGuillonneau B. Prostate cancer: New treatments for localized tumours—what matters first? Nat Rev Urol. 2012; 9 :414–5....
In recent years the pace of research in prostate cancer has increased dramatically. Creative ideas in combination with new and emerging technologies have led to an explosion of discovery. These types of advances in prostate cancer research presage an era of new treatment strategies based on an unde...
has seen remarkable progress. This article, tailored for students from elementary to high school, aims to educate you on the basics of prostate cancer, new therapies, and how these innovations can lead to a cure. Let's dive into the world of medical science...
Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and E... Background Metastatic castration-resistant prostate cancer (mCRPC) and its treatment significantly affect health-related quality of life (HRQOL). Our...
There are some prostate cancer treatments are asActive SurveillanceIf you have a small, slow-growing prostate cancer, a good option is "Active Surveillance." Your doctor will keep an eye on it with tests every few months, like a PSA blood test, biopsy, or maybe an MRI. This way, you ...
Prostate cancer is often an indolent disease, and delays in treatment up to 6 months do not seem to affect cancer-free survival. Inadequate pre-treatment assessment and uninformed shared decision-making can lead to decision regret and disparities in receipt of treatments. Time is on our side to...
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty year...
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiv
Conducting further research will enable us to gain a better understanding of these mechanisms and their impact on the development of cancer. Chronic inflammation preceding PC onset or cooperating with early stages of PC development can be an essential source for new biomarkers that can be used in ...
chemotherapy is given through a special intravenous line in a series of treatments over several months. There have been new advances in both the hormonal and chemotherapy treatment of prostate cancer. Unfortunately, chemotherapy often kills other fast-growing body cells like hair cells, mucosal cells...